TMTaisuke Matsuya

Taisuke Matsuya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Taisuke Matsuya has a total of 65 co-authors. Here are the top co-authors by number of shared publications:

  • Yasuhiro Nakamura

    Department of Skin Oncology/Dermatology Saitama Medical University International Medical Center Saitama Japan

    3 shared publications
  • Anna Kamimura

    Department of Skin Oncology/Dermatology Saitama Medical University International Medical Center Saitama Japan

    2 shared publications
  • Buntaro Yamaguchi

    Department of Skin Oncology/Dermatology Saitama Medical University International Medical Center Saitama Japan

    2 shared publications
  • Jiro Uehara

    Department of Dermatologic Oncology Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan

    2 shared publications
  • Kentaro Yamamura

    Department of Dermatology Kagawa University Faculty of Medicine Miki‐cho Kagawa Japan

    2 shared publications
  • Megumi Aoki

    Department of Dermato‐Oncology/Dermatology National Hospital Organization Kagoshima Medical Center Kagoshima Japan

    2 shared publications

Latest Publications

  • Comparison of surgical morbidities between LigaSure™ and conventional techniques in inguinal or ilioinguinal lymph node dissection for skin cancer: A single center retrospective study

    by Yoshiyasu Umeda, Yukiko Teramoto, Yuri Asami, Taisuke Matsuya, Shintaro Saito, Katsuhito Sasaki, Natsuki Baba, Shoichiro Ishizuki, Anna Kamimura, Buntaro Yamaguchi, et al.

    Skin cancer patients with clinical nodal disease or whose positive sentinel nodes had great tumor burden remain candidates for regional lymph node dissections. Among these patients, inguinal or ilioinguinal lymph node dissection is frequently required in clinical practice, which is associated with significant postoperative morbidity—including lymphatic leakage. The aim of this retrospective study was to evaluate the efficacy of LigaSure™, an electrothermal bipolar vessel sealing system, in reducing lymphatic leakage in inguinal or ilioinguinal lymph node dissection. In total, 58 patients who received inguinal or ilioinguinal lymph node dissection (conventional group, 48; LigaSure™ group, 10) and shared similar characteristics were included in this study. Lymphatic leakage after drain removal was significantly lower in the LigaSure™ group than that in the conventional group (present ratio, 0% vs. 37%; p = 0.02). The daily lymphatic drainage volume also tended to be lower in the LigaSure™ than that in the conventional group, with significant differences on postoperative day 1 (p = 0.02). Other perioperative outcomes including the operating time, intraoperative blood loss, time to drain removal, duration of hospital stay, flap necrosis, and wound infection showed no significant differences between the two groups. The use of the LigaSure™ in inguinal or ilioinguinal lymph node dissection for the treatment of skin cancer could reduce the incidence of postoperative lymphatic leakage after drain removal.


  • Concordance in judgment of clinical borders of basal cell carcinomas in Japanese patients: A preliminary study of JCOG2005 (J‐BASE‐MARGIN)

    by Anna Kamimura, Yasuhiro Nakamura, Tatsuya Takenouchi, Shigeto Matsushita, Toshikazu Omodaka, Kentaro Yamamura, Hiroshi Uchi, Shusuke Yoshikawa, Hiroto Yanagisawa, Takamichi Ito, et al.

    Basal cell carcinoma is the most common type of skin cancer, and surgical excision with clear margins is the standard of care. Surgical margins are determined based on risk factors (high or low risk) for recurrence according to the National Comprehensive Cancer Network and Japanese basal cell carcinoma guidelines. The clarity of the clinical tumor border (well-defined or poorly defined) is considered a risk factor, and significant discrepancies in the judgment of clinical tumor borders among dermato-oncologists may occur. Therefore, we analyzed the dermato-oncologists' concordance in judging the clinical tumor border of basal cell carcinoma. Forty-seven dermato-oncologists (experts: 37; young trainees: 10) participated in this study. The datasets of clinical and dermoscopic photographs of 79 Japanese cases of head and neck basal cell carcinoma were used to determine the concordance in the judgment of clinical tumor border. The probability of the border that was selected more often was used to calculate the rater agreement rate for each dataset. Correct judgment was defined as a more frequently selected border, and the concordance rate of clarity of clinical tumor border for each dermato-oncologist was calculated based on the definition of the correct judgment. A median concordance rate of 85% or higher for all dermato-oncologists was predefined as an acceptable rate for clinical use. Of the 79 datasets, rater agreement rates were 80-100%, 60-79%, and 51-59% for 55, 19, and five datasets, respectively. The median concordance rate for all dermato-oncologists was 86% (interquartile range: 82-89%). There was no significant difference in the concordance rate between the experts and the trainees (median, 87% vs. 85.5%; p = 0.58). The concordance rates of dermato-oncologists for all datasets were relatively high and acceptable for clinical use.


  • Vitiligo expansion and extent correlate with durable response in anti‐programmed death 1 antibody treatment for advanced melanoma: A multi‐institutional retrospective study

    by Taisuke Matsuya, Yasuhiro Nakamura, Shigeto Matsushita, Ryota Tanaka, Yukiko Teramoto, Yuri Asami, Jiro Uehara, Megumi Aoki, Kentaro Yamamura, Yoshiyuki Nakamura, et al.

    Vitiligo is an autoimmune disorder resulting from the destruction of melanocytes. Several reports indicate the association between vitiligo and treatment response in advanced melanoma during immunotherapy. It has not been investigated, however, if an increase of vitiligo while on treatment with anti‐programmed death 1 (PD‐1) antibodies is associated with more durable responses. The aim of this study is to evaluate the correlation between the vitiligo dynamics and clinical efficacy of anti‐PD‐1 antibodies. This study included advanced melanoma patients who were treated with nivolumab or pembrolizumab and developed vitiligo thereafter. Correlation between vitiligo expansion (defined as an increase of lesion size at two separate time points at least 4 weeks apart) as well as vitiligo extent (body surface area [BSA] affected) and clinical efficacy based on response rate, progression‐free survival and overall survival was assessed. We retrospectively reviewed 29 patients. The median time from the initiation of anti‐PD‐1 antibody to vitiligo onset was 4.3 months in patients who showed a response and 5.5 months in patients who showed no response (P = 0.31). Twelve patients showed vitiligo expansion, and in nine of these patients, vitiligo increased to grade 2 (covering ≥ 10% BSA). Vitiligo expansion and grade 2 vitiligo showed no improvement in treatment response (P = 0.59 and 0.25) but were associated with prolonged progression‐free survival (P = 0.019 and 0.04). Grade 2 vitiligo also showed a trend for prolonged overall survival (P = 0.07). Trend of expansion and larger vitiligo extent may be predictive factors of prolonged survival during anti‐PD‐1 antibody in melanoma patients.